Research Progress in the Influence of Proton Pump Inhibitors on Absorption of Oral Targeted Antitumor Drugs

doi:10.19803/j.1672-8629.2021.11.21

Abstract

Abstract: Proton pump inhibitors (PPIs), also called H⁺/K⁺-ATPase inhibitors, not only affect the efficiency and safety of drugs due to their inhibition of gastric acid secretion, resulting in the increase of pH in the stomach, but also hinder the dissolution and absorption of drugs. Oral targeted anticancer drugs are first-line treatment against tumors. Some cancer patients take PPIs and oral targeted anti-tumor drugs at the same time, making it necessary to study the effect of PPIs on the absorption of oral targeted anti-tumor drugs for the sake of effective and safe cancer treatment. In order to provide reference for clinical use, promote rational use of drugs and improve clinical efficacy, this paper collected the related literature and summarized the influence of PPIs on the absorption of oral targeted anti-tumor drugs.

Key words: proton pump inhibitors, oral targeted antitumor drugs, absorption, efficacy

CLC Number:

R979.1

XU Yinying, LU Zihong, LI Qi, LU Mudan, JIANG Sunmin. Research Progress in the Influence of Proton Pump Inhibitors on Absorption of Oral Targeted Antitumor Drugs[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1091-1096.

References

[1] Huang Q, Du J, Cheng SQ, et al.Progress of proton pump inhibitors using in cancer patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2018, 23(10): 105-113.
[2] Smelick GS, Heffron TP, Chu L, et al.Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development[J] . Mol. Pharm, 2013, 10(11): 4055-4062.
[3] Zhang S, Wang MX, Feng ZY, et al.Progress on pharmacokinetic interaction of targeted antitumor drugs[J]. China Pharmacy(中国药房), 2016, 27(20): 2871-2874.
[4] Ding YF, Zhong DF.Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors[J]. Acta Pharmaceutica Sinica(药学学报), 2013, 48(7): 1080-1090.
[5] Schlichtig K, Dürr P, Dörje F, et al.New oral anti-cancer drugs and medication safety[J] . Dtsch Arztebl Int, 2019, 116(46): 775-782.
[6] Kumarakulasinghe NB, Syn N, Soon YY, et al.EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction[J]. Oncotarget, 2016, 7: 85542-85550.
[7] Kletzl H, Giraudon M, Abt M, et al.Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: Omeprazole and ranitidine[J]. Anti-Cancer Drugs, 2015, 26(5): 565-72.
[8] Ohgami M, Kaburagi T, Kurosawa A, et al.Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer[J]. Ther Drug Monit, 2018, 40(6): 699-704.
[9] Chu MP, Ghosh S, Chambers CR, et al.Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer[J]. Clinical Lung Cancer, 2015, 16(1): 33-39.
[10] Heine RT, Fanggiday JC, Lankheet NAG, et al.Erlotinib and pantoprazole: a relevant interaction or not?[J]. British Journal of Clinical Pharmacology, 2010, 70(6): 908-911.
[11] Yasumuro O, Uchida S, Kashiwagura Y, et al.Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats[J]. Xenobiotica, 2018, 48(11): 1106-1112.
[12] Niho S, You Y, Zenke k, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations[J] . Clin Lung Cancer, 2016, 17(5), 412-418.
[13] Fang YH, Yang YH, Hsieh MJ, et al.Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment-a nationwide population-based study[J]. Cancer Manag Res, 2019, 11: 8539-8546.
[14] Vishwanathan K, Dickinson PA, Bui K, et al.The Effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers[J]. J Clin Pharmacol, 2018, 58(4): 474-484.
[15] Hamilton G, Rath B, Burghuber O.Pharmacokinetics of crizotinib in NSCLC patients[J]. Expert Opinion on Drug Metabolism & Toxicology, 2015, 11(5): 835-842.
[16] Hirota T, Muraki S, Ieiri I.Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer[J]. Clinical Pharmacokinetics, 2019, 58(4): 403-420.
[17] Hong Y, Passos VQ, Huang PH, et al.Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase[J]. The Journal of Clinical Pharmacology, 2017, 57(5): 652-662.
[18] Lau YY, Gu W, Lin T, et al.Assessment of drug drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer[J]. Cancer Chemotherapy and Pharmacology, 2017, 79(6): 1119-1128.
[19] Escudier DB, Gore M.Axitinib for the management of metastatic renal cell carcinoma[J]. Drugs in R & D, 2011, 11(2): 113-126.
[20] Rugo HS.Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results[J]. Journal of Clinical Oncology, 2005, 23(24): 5474-5483.
[21] Lalani AKA, Mckay RR, Lin X, et al.Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma[J]. Clin Genitourin Cancer, 2017, 15(6): 724-732.
[22] Tan AR, Gibbon DG, Stein MN, et al.Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors[J]. Cancer Chemotherapy and Pharmacology, 2013, 71(6): 1635-1643.
[23] Mcalister RK, Aston J, Pollack M, et al.Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma[J]. Oncologist, 2018, 23(6): 686-692.
[24] Koch KM, Young-Hyuck I, Sung-Bae K, et al.Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients[J]. Clin Pharmacol Drug Dev, 2013, 2(4): 336-341.
[25] Ruiz-Garcia A, Masters JC, Laure MDC, et al.Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers[J]. The Journal of Clinical Pharmacology, 2016, 56(2): 223-230.
[26] Egorin MJ, Shah DD, Christner SM, et al.Effect of a proton pump inhibitor on the pharmacokinetics of imatinib[J]. British Journal of Clinical Pharmacology, 2009, 68(3): 370-374.
[27] White DL, Eadie LN, Saunders VA, et al.Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells[J]. Leukemia, 2013, 27(5): 1201-1204.
[28] Xu H, Ma LL, Xu W, et al.A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration[J]. Chinese Journal of Gastrointestinal Surgery(中华胃肠外科杂志), 2016, 19(11): 1271-1276.
[29] Récoché I, Rousseau V, Bourrel R, et al.Drug-drug interactions with imatinib: An observational study[J]. Medicine (Baltimore), 2016, 95(40): e5076.
[30] Hořínková J, Šíma M, Slanař O.Pharmacokinetics of dasatinib[J]. Prague Med Rep, 2019, 120(2): 52-63.
[31] Takahashi N, Miura M, Niioka T, et al.Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmaco-kinetics in Japanese leukemia patients[J]. Cancer Chemother Pharmacol, 2012, 69(4): 999-1004.
[32] Yago MR, Frymoyer A, Benet LZ, et al.The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria[J]. The AAPS Journal, 2014, 16(6): 1358-1365.
[33] Santiago O, Vicente EV, Gómez-Centurión Ignacio, et al.Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?[J]. Ann Hematol, 2018, 97(11): 2089-2098.
[34] Yin OQ, Gallagher N, Fischer D, et al.Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.[J]. J Clin Pharmacol, 2010, 50(8): 960-967.
[35] Yin OQP, Frank J.Giles. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia[J]. Cancer Chemotherapy and Pharmacology, 2012, 70(2): 345-350.
[36] Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI, et al.Sorafenib[J]. Profiles Drug Subst Excip Relat Methodol, 2019, 44: 239-266.
[37] Lind JSW, Dingemans AMC, Groen HJM, et al.A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer[J]. Clinical Cancer Research, 2010, 16(11): 3078-3087.
[38] Flaherty KT, Lathia C, Frye RF, et al.Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study[J]. Cancer Chemother Pharmacol, 2011, 68(5): 1111-1118.
[39] Bilbao-Meseguer I, Jose BS, Lopez-Gimenez LR, et al.Drug interactions with sunitinib[J]. J Oncol Pharm Pract, 2015, 21(1): 52-66.
[40] Ha VH, Ngo M, Chu MP, et al.Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?[J]. Journal of Oncology Pharmacy Practice, 2015, 21(3): 194-200.
[41] Femke MDM, Koen GAMH, Mirjam DW, et al.Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib: a randomized crossover pharmac-okinetic study[J]. Clin Pharmacol Ther, 2019, 105(6): 1456-1461.
[42] Budha NR, Frymoyer A, Smelick GS, et al.Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?[J]. Clin Pharmacol Ther, 2012, 92(2): 203-213.